Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Malignant Gliomas: Simplifying the Complexity.

Fine HA.

Cancer Discov. 2019 Dec;9(12):1650-1652. doi: 10.1158/2159-8290.CD-19-1081.

PMID:
31792122
2.

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

Sailer V, Eng KW, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E, Cyrta J, Rao R, Sahota S, Pauli C, Beg S, Motanagh S, Kossai M, Fontunge J, Puca L, Rennert H, Zhaoying Xiang J, Greco N, Kim R, MacDonald TY, McNary T, Blattner-Johnson M, Schiffman MH, Faltas BM, Greenfield JP, Rickman D, Andreopoulou E, Holcomb K, Vahdat LT, Scherr DS, van Besien K, Barbieri CE, Robinson BD, Fine HA, Ocean AJ, Molina A, Shah MA, Nanus DM, Pan Q, Demichelis F, Tagawa ST, Song W, Mosquera JM, Sboner A, Rubin MA, Elemento O, Beltran H.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00047. Epub 2019 Sep 20.

3.

Grading meningiomas utilizing multiparametric MRI with inclusion of susceptibility weighted imaging and quantitative susceptibility mapping.

Zhang S, Chiang GC, Knapp JM, Zecca CM, He D, Ramakrishna R, Magge RS, Pisapia DJ, Fine HA, Tsiouris AJ, Zhao Y, Heier LA, Wang Y, Kovanlikaya I.

J Neuroradiol. 2019 May 25. pii: S0150-9861(19)30162-2. doi: 10.1016/j.neurad.2019.05.002. [Epub ahead of print]

PMID:
31136748
4.

Modeling Patient-Derived Glioblastoma with Cerebral Organoids.

Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, Milner T, Reich B, Cohen-Gould L, Storaska A, Nakayama Y, Schenkein E, Singhania R, Cirigliano S, Magdeldin T, Lin Y, Nanjangud G, Chadalavada K, Pisapia D, Liston C, Fine HA.

Cell Rep. 2019 Mar 19;26(12):3203-3211.e5. doi: 10.1016/j.celrep.2019.02.063.

5.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.

Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA.

J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.

PMID:
30882547
6.

Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling.

Seligman L, Kovanlikaya I, Pisapia DJ, Naeger DM, Magge R, Fine HA, Chiang GC.

AJR Am J Roentgenol. 2019 Apr;212(4):883-891. doi: 10.2214/AJR.18.20531. Epub 2019 Feb 19.

PMID:
30779663
7.

MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.

Ivanidze J, Lum M, Pisapia D, Magge R, Ramakrishna R, Kovanlikaya I, Fine HA, Chiang GC.

J Neuroimaging. 2019 May;29(3):357-363. doi: 10.1111/jon.12596. Epub 2019 Jan 15.

PMID:
30644143
8.

Texture analysis on conventional MRI images accurately predicts early malignant transformation of low-grade gliomas.

Zhang S, Chiang GC, Magge RS, Fine HA, Ramakrishna R, Chang EW, Pulisetty T, Wang Y, Zhu W, Kovanlikaya I.

Eur Radiol. 2019 Jun;29(6):2751-2759. doi: 10.1007/s00330-018-5921-1. Epub 2019 Jan 7.

PMID:
30617484
9.

MRI based texture analysis to classify low grade gliomas into astrocytoma and 1p/19q codeleted oligodendroglioma.

Zhang S, Chiang GC, Magge RS, Fine HA, Ramakrishna R, Chang EW, Pulisetty T, Wang Y, Zhu W, Kovanlikaya I.

Magn Reson Imaging. 2019 Apr;57:254-258. doi: 10.1016/j.mri.2018.11.008. Epub 2018 Nov 19.

PMID:
30465868
10.

Detailed longitudinal sampling of glioma stem cells in situ reveals Chr7 gain and Chr10 loss as repeated events in primary tumor formation and recurrence.

Baysan M, Woolard K, Cam MC, Zhang W, Song H, Kotliarova S, Balamatsias D, Linkous A, Ahn S, Walling J, Belova GI, Fine HA.

Int J Cancer. 2017 Nov 15;141(10):2002-2013. doi: 10.1002/ijc.30887. Epub 2017 Aug 21.

11.

A Core Regulatory Circuit in Glioblastoma Stem Cells Links MAPK Activation to a Transcriptional Program of Neural Stem Cell Identity.

Riddick G, Kotliarova S, Rodriguez V, Kim HS, Linkous A, Storaska AJ, Ahn S, Walling J, Belova G, Fine HA.

Sci Rep. 2017 Mar 3;7:43605. doi: 10.1038/srep43605.

12.

A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.

Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, Fine HA.

CNS Oncol. 2016;5(2):59-67. doi: 10.2217/cns-2015-0010. Epub 2016 Feb 10.

13.

A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.

Odia Y, Iwamoto FM, Moustakas A, Fraum TJ, Salgado CA, Li A, Kreisl TN, Sul J, Butman JA, Fine HA.

J Neurooncol. 2016 Mar;127(1):127-35. doi: 10.1007/s11060-015-2020-x. Epub 2015 Dec 7.

PMID:
26643807
14.

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

Odia Y, Kreisl TN, Aregawi D, Innis EK, Fine HA.

J Neurooncol. 2015 Oct;125(1):191-5. doi: 10.1007/s11060-015-1894-y. Epub 2015 Aug 19.

PMID:
26285768
15.

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.

Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992. doi: 10.1016/j.ijrobp.2015.04.038. Epub 2015 Apr 30.

16.

New strategies in glioblastoma: exploiting the new biology.

Fine HA.

Clin Cancer Res. 2015 May 1;21(9):1984-8. doi: 10.1158/1078-0432.CCR-14-1328. Epub 2015 Feb 10. Review.

17.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD.

J Clin Oncol. 2015 Mar 1;33(7):786-809. doi: 10.1200/JCO.2014.59.9746. Epub 2015 Jan 20. Review. No abstract available.

PMID:
25605863
18.

Correction to "master regulators, regulatory networks, and pathways of glioblastoma subtypes".

Bozdag S, Li A, Baysan M, Fine HA.

Cancer Inform. 2014 Nov 30;13(Suppl 3):91. doi: 10.4137/CIN.S22020. eCollection 2014.

19.

An in silico screen links gene expression signatures to drug response in glioblastoma stem cells.

Riddick G, Song H, Holbeck SL, Kopp W, Walling J, Ahn S, Zhang W, Fine HA.

Pharmacogenomics J. 2015 Aug;15(4):347-53. doi: 10.1038/tpj.2014.61. Epub 2014 Dec 2.

PMID:
25446780
20.

Master regulators, regulatory networks, and pathways of glioblastoma subtypes.

Bozdag S, Li A, Baysan M, Fine HA.

Cancer Inform. 2014 Oct 15;13(Suppl 3):33-44. doi: 10.4137/CIN.S14027. eCollection 2014. Erratum in: Cancer Inform. 2014;13(Suppl 3):91.

21.

Identification of molecular pathways facilitating glioma cell invasion in situ.

Nevo I, Woolard K, Cam M, Li A, Webster JD, Kotliarov Y, Kim HS, Ahn S, Walling J, Kotliarova S, Belova G, Song H, Bailey R, Zhang W, Fine HA.

PLoS One. 2014 Nov 3;9(11):e111783. doi: 10.1371/journal.pone.0111783. eCollection 2014.

22.

Timing (and biology) are everything.

Fine HA.

Neuro Oncol. 2014 Nov;16(11):1431-2. doi: 10.1093/neuonc/nou285. Epub 2014 Oct 14. No abstract available.

23.

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii36-47. doi: 10.1093/neuonc/nou226.

24.

Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.

Bastien JI, McNeill KA, Fine HA.

Cancer. 2015 Feb 15;121(4):502-16. doi: 10.1002/cncr.28968. Epub 2014 Sep 23. Review.

25.

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.

Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA.

J Immunother Cancer. 2014 Aug 19;2:25. doi: 10.1186/2051-1426-2-25. eCollection 2014.

26.

Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.

Odia Y, Shih JH, Kreisl TN, Fine HA.

J Neurooncol. 2014 Nov;120(2):431-40. doi: 10.1007/s11060-014-1571-6. Epub 2014 Aug 7.

PMID:
25098701
27.

How to get from here to there: tracking down invasive glioma cells.

Fine HA.

J Natl Cancer Inst. 2014 May 16;106(6):dju120. doi: 10.1093/jnci/dju120. Print 2014 Jun. No abstract available.

PMID:
24838836
28.

Micro-environment causes reversible changes in DNA methylation and mRNA expression profiles in patient-derived glioma stem cells.

Baysan M, Woolard K, Bozdag S, Riddick G, Kotliarova S, Cam MC, Belova GI, Ahn S, Zhang W, Song H, Walling J, Stevenson H, Meltzer P, Fine HA.

PLoS One. 2014 Apr 11;9(4):e94045. doi: 10.1371/journal.pone.0094045. eCollection 2014.

29.

Bevacizumab in glioblastoma--still much to learn.

Fine HA.

N Engl J Med. 2014 Feb 20;370(8):764-5. doi: 10.1056/NEJMe1313309. No abstract available.

PMID:
24552324
30.

ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state.

Chudnovsky Y, Kim D, Zheng S, Whyte WA, Bansal M, Bray MA, Gopal S, Theisen MA, Bilodeau S, Thiru P, Muffat J, Yilmaz OH, Mitalipova M, Woolard K, Lee J, Nishimura R, Sakata N, Fine HA, Carpenter AE, Silver SJ, Verhaak RG, Califano A, Young RA, Ligon KL, Mellinghoff IK, Root DE, Sabatini DM, Hahn WC, Chheda MG.

Cell Rep. 2014 Jan 30;6(2):313-24. doi: 10.1016/j.celrep.2013.12.032. Epub 2014 Jan 16.

31.

The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D).

Lai JP, Liu YC, Alimchandani M, Liu Q, Aung PP, Matsuda K, Lee CC, Tsokos M, Hewitt S, Rushing EJ, Tamura D, Levens DL, Digiovanna JJ, Fine HA, Patronas N, Khan SG, Kleiner DE, Oberholtzer JC, Quezado MM, Kraemer KH.

Acta Neuropathol Commun. 2013 May 8;1:4. doi: 10.1186/2051-5960-1-4.

32.

A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma.

Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12. doi: 10.1016/j.jchromb.2013.10.023. Epub 2013 Oct 22.

33.

Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.

Ho J, Ondos J, Ning H, Smith S, Kreisl T, Iwamoto F, Sul J, Kim L, McNeil K, Krauze A, Shankavaram U, Fine HA, Camphausen K.

PLoS One. 2013 Aug 5;8(8):e70745. doi: 10.1371/journal.pone.0070745. Print 2013.

34.

Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels.

Bozdag S, Li A, Riddick G, Kotliarov Y, Baysan M, Iwamoto FM, Cam MC, Kotliarova S, Fine HA.

PLoS One. 2013 Apr 29;8(4):e62982. doi: 10.1371/journal.pone.0062982. Print 2013.

35.

Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.

Ene CI, Edwards L, Riddick G, Baysan M, Woolard K, Kotliarova S, Lai C, Belova G, Cam M, Walling J, Zhou M, Stevenson H, Kim HS, Killian K, Veenstra T, Bailey R, Song H, Zhang W, Fine HA.

PLoS One. 2012;7(12):e51407. doi: 10.1371/journal.pone.0051407. Epub 2012 Dec 7.

36.

G-cimp status prediction of glioblastoma samples using mRNA expression data.

Baysan M, Bozdag S, Cam MC, Kotliarova S, Ahn S, Walling J, Killian JK, Stevenson H, Meltzer P, Fine HA.

PLoS One. 2012;7(11):e47839. doi: 10.1371/journal.pone.0047839. Epub 2012 Nov 6.

37.

A phase I/II trial of vandetanib for patients with recurrent malignant glioma.

Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA.

Neuro Oncol. 2012 Dec;14(12):1519-26. doi: 10.1093/neuonc/nos265. Epub 2012 Oct 25.

38.

Continuous daily sunitinib for recurrent glioblastoma.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA.

J Neurooncol. 2013 Jan;111(1):41-8. doi: 10.1007/s11060-012-0988-z. Epub 2012 Oct 20.

PMID:
23086433
39.

A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).

Alexander BM, Wang M, Yung WK, Fine HA, Donahue BA, Tremont IW, Richards RS, Kerlin KJ, Hartford AC, Curran WJ, Mehta MP.

J Neurooncol. 2013 Jan;111(1):33-9. doi: 10.1007/s11060-012-0987-0. Epub 2012 Oct 20.

PMID:
23086432
40.

Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc.

Kim HS, Woolard K, Lai C, Bauer PO, Maric D, Song H, Li A, Kotliarova S, Zhang W, Fine HA.

Cancer Res. 2012 Nov 15;72(22):6065-75. doi: 10.1158/0008-5472.CAN-12-2594. Epub 2012 Sep 17.

41.

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.

Hum Gene Ther. 2012 Oct;23(10):1043-53. doi: 10.1089/hum.2012.041. Epub 2012 Sep 24.

42.

SnapShot: glioblastoma multiforme.

Kotliarova S, Fine HA.

Cancer Cell. 2012 May 15;21(5):710-710.e1. doi: 10.1016/j.ccr.2012.04.031. No abstract available.

43.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

44.

Refining endpoints in brain tumor clinical trials.

Meyers CA, Rock EP, Fine HA.

J Neurooncol. 2012 Jun;108(2):227-30. doi: 10.1007/s11060-012-0813-8. Epub 2012 Mar 27.

PMID:
22451194
45.

Many tumors in one: a daunting therapeutic prospect.

Ene CI, Fine HA.

Cancer Cell. 2011 Dec 13;20(6):695-7. doi: 10.1016/j.ccr.2011.11.018.

46.

Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma.

Fraum TJ, Barak S, Pack S, Lonser RR, Fine HA, Quezado M, Iwamoto FM.

J Neurooncol. 2012 Apr;107(2):421-6. doi: 10.1007/s11060-011-0760-9. Epub 2011 Nov 15.

PMID:
22083647
47.

Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation.

Aguda BD, Kim Y, Kim HS, Friedman A, Fine HA.

Biophys J. 2011 Nov 2;101(9):2082-91. doi: 10.1016/j.bpj.2011.09.052. Epub 2011 Nov 1.

48.

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA.

Neuro Oncol. 2011 Oct;13(10):1143-50. doi: 10.1093/neuonc/nor091. Epub 2011 Aug 24.

49.

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2011 Oct;13(10):1118-24. doi: 10.1093/neuonc/nor110. Epub 2011 Aug 2.

50.

Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion.

Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, Mantey SA, Maric D, Song H, Belova G, Jensen RT, Zhang W, Fine HA.

J Natl Cancer Inst. 2011 Aug 3;103(15):1162-78. doi: 10.1093/jnci/djr224. Epub 2011 Jul 19.

Supplemental Content

Support Center